ORLADEYO demonstrated significant HAE attack rate reduction over 24 weeks1
- APeX-2 part 1 was a double-blind, placebo-controlled study (N=121)1,a
- Patients treated with ORLADEYO 150 mg saw an attack rate reduction from 3.06 to 1.31 attacks per month2
- Patients receiving placebo saw a reduction from 2.91 to 2.35 attacks per month2
ORLADEYO offers significant and sustained attack prevention, with results seen within the first 4 weeks and maintained over 96 weeks.1,3
aThe percent reduction in attack rate was greater with ORLADEYO 150 mg (n=40) relative to placebo (n=39) regardless of attack rate during the run-in period.1
![](https://orladeyo.kinsta.cloud/wp-content/uploads/icon-91.png)
ATTACK RATE REDUCTION FROM BASELINE AT 96 WEEKS3,b
aThe percent reduction in attack rate was greater with ORLADEYO 150 mg (n=40) relative to placebo (n=39) regardless of attack rate during the run-in period.1
bDue to study design, investigator-confirmed attack rates were reported only during the first 48 weeks, while patient-reported attack rates were reported during weeks 49 to 96. For consistency across the entire 96 weeks, only patient-reported attack rates are reported. For analysis purposes, 1 month was defined as 4 weeks of treatment.3
cAdjusted patient-reported attack rates were defined as the total number of adjusted patient-reported HAE attacks experienced in a period, adjusted for the length of a month (defined as 28 days) and the number of days during that period.3
aThe percent reduction in attack rate was greater with ORLADEYO 150 mg (n=40) relative to placebo (n=39) regardless of attack rate during the run-in period.1
![Bill Lumry, HAE specialist physician and ORLADEYO prescriber, and hypothetical HAE patient](https://orladeyo.kinsta.cloud/wp-content/uploads/doctor-1.png)
Starting patients strong
Setting treatment expectations is an integral part of treatment adherence.
Ready to get started?
Real experiences of switching
Hear about a patient‘s experience switching to ORLADEYO from another prophylaxis.
![](https://orladeyo.kinsta.cloud/wp-content/uploads/hcp-dr-stewart.png)
“I think there‘s a misperception among other healthcare providers that ORLADEYO is not effective because it‘s an oral medication. I like to inform them about the efficacy of ORLADEYO; I think that information is reassuring.”
– Patricia Stewart, MD
a prescriber of ORLADEYO
To date, no studies to evaluate ORLADEYO against an active comparator have been conducted.